Skip to main content
x
About searching

Search results

  1. Acrivon CHKs itself

    … 2 trial of ACR-368   Mar 2025 update ESMO 2024 Patient subgroup BM+ BM- …

    - 03/27/2025 - 13:27

  2. SGO 2025 – Genmab’s advantage looks Profound

    … cohort B1 results   SGO 2025 ESMO 2024 Cutoff date 15 Jan 2025 28 Jul …

    - 03/20/2025 - 16:08

  3. Merck and Sanofi sound the alarm for ILT inhibition

    … of BND-22 had posted “encouraging results”. However, an ESMO 2024 presentation suggests otherwise and there must now …

    - 03/07/2025 - 18:26

  4. GSK and Hansoh press on despite Pfizer’s exit

    … AstraZeneca ADC Ph1/2 underwhelmed at ESMO 2024, with ORR 25% in ≥25% expressers …

    - 03/06/2025 - 13:28

  5. Bristol exits KRAS G12D

    … Astellas Degrader Lacklustre ph1 data at ESMO 2024; proof-of-concept judgement due in H1 2025 …

    - 03/06/2025 - 13:30

  6. The month ahead: March's upcoming events

    … dosing in Jul 2024; 8 treatment-related deaths reported at ESMO 2024 Source: OncologyPipeline.   …

    - 03/21/2025 - 08:31

  7. Regeneron’s Met bet falls short

    … x Met bispecific MAb Ph1/2 in Met-altered NSCLC ESMO 2024: ORR 12% (9/74) in pts receiving 2000mg …

    - 04/16/2025 - 15:49

  8. What future for Lag3 blockade?

    … Ph2 chemo combo, failed on PFS vs Opdivo + chemo at ESMO 2024; numerical benefit in post-hoc non-sq 1-49% PD-L1 …

    - 02/18/2025 - 15:54

  9. The month ahead: February’s upcoming events

    … dosing in Jul 2024; 8 treatment-related deaths reported at ESMO 2024 Source: OncologyPipeline. …

    - 02/04/2025 - 16:15

  10. Daiichi ups its Glycotope bet

    … None Ph1 in Claudin6+ve solid tumours; initial data at ESMO 2024: Source: OncologyPipeline. …

    - 01/16/2025 - 13:06